Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized study in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab As Front-Line Therapy

Next Previous
Search
Trial Profile

Randomized study in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab As Front-Line Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Obinutuzumab (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms ALLG CLL7

    • Most Recent Events

    • 23 Jan 2019 New trial record
    • 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top